Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

September 30, 2024 / 2024 Power 25 Health Care

2024 Power 25 Health Care: Michael Aberman & Jay Markowitz

Michael Aberman

Talk about returning with a bang.

Dr. Michael Aberman, then-senior vice president of strategy and investor relations, left New York-based Regeneron Pharmaceuticals in July 2017 to lead an emerging private biotechnology company.

Three years later, Dr. Jay S. Markowitz, senior vice president of portfolio management, departed Regeneron in February 2020 to pursue a new opportunity within the investment community.

Fast-forward to April 2024, when both Aberman and Markowitz returned to lead Regeneron Ventures, a Greenwich-based biotech venture capital fund that launched with a five-year, $500 million commitment from its exclusive limited partner, Regeneron Pharmaceuticals.

The pharmaceutical company said it has committed $100 million annually for five years to the venture capital fund, which will focus on “promising” biopharmaceutical, health care and health technology companies.

Both Markowitz and Aberman began their professional careers in medicine before switching to investing and operational roles in biotech.

Before joining Regeneron Ventures, Aberman was CEO and co-founder of XenImmune Therapeutics, a seed stage biotech company. He also previously served as president and CEO of Quentis Therapeutics, an early-stage biotech company.

Markowitz joined Regeneron Ventures from ARCH Venture Partners, where he was a senior partner. In his three years at ARCH, he was a founder of three companies and served as a board member and advisor for two others.

He has 16 years of public market investment experience at T. Rowe Price Associates and Capital World Investors, where he focused on the biotechnology and pharmaceutical industry.

Sign up for Enews

0 Comments

Order a PDF